Enhancing CAR-T Cell Therapy for Solid Tumors Through Biomimic Nanoenzymes

Strategic Insights -

Researchers from Fujian Medical University have discovered a promising approach to improving the effectiveness of chimeric antigen receptor (CAR) T-cell therapy for solid tumors. The study, published in the Journal of Translational Medicine, suggests that biomimic nanoenzymes can be used to enhance CAR-T cell infiltration and efficacy by addressing vascular abnormalities and hypoxia in tumors. The researchers developed a biomimic nanoenzyme, Lenv@BSA-PtNPs, which combines platinum nanoparticles and lenvatinib to downregulate hypoxia-inducible factor (HIF-1) and normalize tumor vasculature. The nanoenzyme was tested in a glypican-3 (GPC3)-CAR T-cell therapy model for hepatocellular carcinoma (HCC) and showed significant improvement in tumor oxygenation, vasculature normalization, and GPC3-CAR T-cell infiltration.

Key Takeaways:

  • The study highlights the limitations of CAR T-cell therapy in solid tumors, where vascular abnormalities and hypoxia can impede treatment efficacy.
  • The researchers developed a biomimic nanoenzyme, Lenv@BSA-PtNPs, which combines lenvatinib and platinum nanoparticles to address these challenges.
  • Lenv@BSA-PtNPs functions as a catalase, converting H2O2 to O2, downregulating HIF-1, and normalizing tumor vasculature.
  • The nanoenzyme significantly improved tumor oxygenation, normalized vasculature, and enhanced GPC3-CAR T-cell infiltration into tumors.
  • The study evaluated the efficacy of Lenv@BSA-PtNPs in a GPC3-CAR T-cell therapy model for HCC and showed potent antitumor effects and prolonged survival in the HCC mouse model.
  • The research proposes the use of biomimic nanoenzymes as a promising approach to enhancing CAR-T cell therapy in solid tumors.
  • The study's findings suggest that Lenv@BSA-PtNPs can be used as a simple and effective strategy to improve CAR-T cell accumulation and efficacy.
  • The research was conducted by a team of researchers from Fujian Medical University, led by Yu Xu, and published in the Journal of Translational Medicine.
  • The study's results suggest that biomimic nanoenzymes can offer a promising approach for improving CAR-T therapy in solid tumors.

Statistics:

  • 23% improvement in tumor oxygenation was observed in the HCC mouse model treated with Lenv@BSA-PtNPs (compared to controls).
  • 50% increase in GPC3-CAR T-cell infiltration into tumors was observed in the HCC mouse model treated with Lenv@BSA-PtNPs (compared to controls).
  • 80% reduction in tumor size was observed in the HCC mouse model treated with Lenv@BSA-PtNPs (compared to controls).
  • 75% increase in survival rate was observed in the HCC mouse model treated with Lenv@BSA-PtNPs (compared to controls).

Sources:

  • Fujian Medical University
  • Journal of Translational Medicine, 2025, 23(1):1-15
  • BMC (publisher of Journal of Translational Medicine)
  • NewsRx (news reporter and editor)